Business / Finance

RSS

Aerocrine acquires FENO technology platform and intellectual property from FILT

Aerocrine AB today announced the acquisition of key assets related to the measurement of FENO from German company FILT Lungen & Thoraxdiagnostik GmbH. FILT and Aerocrine will collaborate to develop new applications for airway inflammation monitoring and FILT will cease further commercialization of the NO VARIO® product.

18 Mar 2011

Affymax prices underwritten public offering of common stock

Affymax, Inc., today announced the pricing of an underwritten public offering of 8,474,576 shares of its common stock at a price to the public of $5.90 per share. The gross proceeds to Affymax from this offering are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

18 Mar 2011

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.

From Quest Diagnostics 18 Mar 2011

Celera reports net revenue of $34.9 million for fourth quarter of 2010

Celera Corporation today reported net revenues of $34.9 million for the fourth quarter of 2010 that ended December 25, 2010, compared to $39.2 million for the prior year quarter.

18 Mar 2011

Cortex reports net loss of $0.01 per share for quarter ended December 31, 2010

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $984,000, or $0.01 per share for the quarter ended December 31, 2010 compared with a net loss of $1,599,000, or $0.02 per share for the corresponding prior year period.

18 Mar 2011

Medical Facilities fourth quarter consolidated facility service revenue increases 10.9% to $64.4 million

Medical Facilities Corporation, today reported its financial results for the three- and twelve-month periods ended December 31, 2010.

18 Mar 2011

MHA hosts two-day Long Term Care Business Summit at ARIA

Managed Health Care Associates, Inc., a leading health care service company focused on alternate site health care providers, is hosting its 8th Annual MHA Business Summit for Long Term Care Pharmacies and other Long Term Care stakeholders on March 17th-18th at ARIA at CityCenter in Las Vegas, Nevada.

18 Mar 2011

Protalix prices underwritten public offering of 4,000,000 shares of common stock

Protalix BioTherapeutics, Inc., announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $5.50 per share.

18 Mar 2011

S&P Healthcare Economic Composite Index for 12-month period ending January 2011 is 6.29%

Data released today by Standard & Poor's for the S&P Healthcare Economic Composite Index indicate that the average per capita cost of healthcare services covered by commercial insurance and Medicare programs increased by 6.29% over the 12-months ending January 2011.

18 Mar 2011

Nature's Health announces record sales of 145% for Australian Dream pain relief cream

Nature's Health Connection has announced record sales of their Australian Dream pain relief cream. After a successful television advertising campaign produced by CPG specialists Western Creative, Inc. that highlights Australian Dream's Empty Jar Guarantee, unit retail sales of the product have increased an astonishing 145% over the course of the last year.

18 Mar 2011

Alnylam to defend against Tekmira complaint

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is reporting the filing of a complaint by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court. The complaint alleges misappropriation and misuse of information, amongst other allegations.

18 Mar 2011

Cangene second quarter revenues increase 3% to $40.2 million

Cangene Corporation today reports financial results for the quarter ended January 31, 2011, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

18 Mar 2011

ACAP selects ArpegioHealth as vendor for business strategy services

National management consulting firm ArpegioHealth announced today it has been selected by the Association for Community Affiliated Plans as a preferred vendor for business strategy.

18 Mar 2011

Protalix intends to sell shares of its common stock in underwritten public offering

Protalix BioTherapeutics, Inc. announced today that it intends, subject to market conditions, to offer and sell shares of its common stock in an underwritten public offering.

18 Mar 2011

China Botanic first quarter net sales increase 32.1% to $22.6 million

China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced financial results for the three months ended January 31, 2011, and reaffirmed guidance for its full fiscal year ending October 31, 2011.

17 Mar 2011

Sparton announces contract manufacturing award from Talyst

Sparton Corporation, a supplier of complex and reliable electronic and electro-mechanical products, sub-assemblies and related services to the highly regulated Medical, Defense & Security, and Aerospace markets, announces an initial contract manufacturing award from Talyst, Inc. located in Bellevue, WA.

17 Mar 2011

China-Biotics supplies additional 3 new strain formulas to Bright Dairy

China-Biotics, Inc., the leading developer, manufacturer and distributor of probiotics products in China, today announced that the Company has expanded its categories of strain formula supplied to Bright Dairy.

17 Mar 2011

lululemon's fourth quarter net revenue increases 53% to $245.4 million

lululemon athletica inc. today announced financial results for the fourth quarter and fiscal year ended January 30, 2011.

17 Mar 2011

Astellas to acquire all Maxygen's equity interests in Perseid for $76.0 million

Maxygen, Inc. today announced that Astellas Pharma Inc. has exercised its option to purchase all of Maxygen's equity interests in Perseid Therapeutics LLC at the current exercise price of $76.0 million.

17 Mar 2011

CBAI to operate its own business strategies

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today the focus of the Company on a go forward basis is to operate entirely off its own cash flow.

17 Mar 2011